BMSN - Bio-Matrix Scientific - Drug-Stocks Boom $

 

 www.americanbulls.com/SignalPage.aspx

 

null  

..na ja, ich habe noch nie etwas von Cartanalysen gehalten...

 

 

 

 ih.advfn.com/p.php

 

Hat Bmsn Benetic somit aufgekauft?

 

www.benitec.com/

 

 Kamen nur käufe also wurde der 8k news positiv aufgefasst

 

 www.youtube.com/watch

 

Wie es ab 15:30 aussieht, vielleicht reicht es um die Aktie anzustoßen und ein bisschen Schwung reinzubringen.  

http://www.benitec.com/documents/REGENLICENCEFORCANCERVACCINES.pdf

 

.

 

das Unternehmen nutzt seine Möglichkeiten - auch zur Kooperation - sehr gut.
Sollte mich nicht wundern, wenn es hier bald richtig heiss her geht....

 

 Pusht benetic biomatrix?

 

Anscheinend nicht......  

 

Also ich bin ziemlich sicher dass die Nachricht noch für einen gewaltigen Kursanstieg verantwortlich sein wird! So im Jahre 2020-2025.......

Ne ernsthaft, solange die Zocker keinen Bock haben und nicht gerade eine Übernahme verkündet wird, bleiben wir auf dem aktuellen Stand...... Wir müssen eben hoffen das ein der beiden Möglichkeiten vor dem endgültigen Exodus passieren wird.  

 

Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its  wholly owned subsidiary, Regen BioPharma Inc. executed a license  agreement with the clinical stage biotechnology company, Benitec  Biopharma Ltd. (ASX: BLT) for the development of vaccines using  Benitec's ddRNAi gene silencing technology.

Benitec's licence to Regen covers the application of ddRNAi to silence  indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is  associated with immune-suppression and is over-expressed in cancer.  Regen has produced pre-clinical evidence that modification of these  cells using ddRNAi targeting the silencing of IDO should significantly  enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed  publication describing this work was published in the February 2013  issue of the International Journal of Cancer (Zheng et al. Silencing IDO  in dendritic cells: a novel approach to enhance cancer immunotherapy in  a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77).  While the terms are commercial-in-confidence, they are within the  expected guidelines for small biotechnology companies in the early stage  of therapeutic development, with fees based on the achievement of  agreed milestones.

Chief Executive Officer of Benitec Biopharma Ltd, Dr. Peter French,  commented, "Benitec is very pleased to have executed this licensing deal  with Regen BioPharma. Using ddRNAi to manipulate Dendritic Cells to  stimulate the immune system to kill cancer cells is an innovative  concept for the treatment of cancer in a non-toxic manner. Regen joins a  growing list of biotechnology companies that have recognised the  advantage of licensing Benitec's transformational gene silencing  technology, ddRNAi, to develop novel therapies for human disease. For  Benitec this provides the opportunity to generate additional evidence  that validates and reinforces the potential of our platform technology."

Chairman & Chief Executive Officer of Regen BioPharma, Dr. David  Koos, commented, "Benitec is the leader in clinical development of  ddRNAi, which allows for 'gene-specific surgery.' By combining our  existing data with the issued patents and experience of Benitec, we look  forward to developing an immune-based, non-toxic, cancer treatment  initially targeting breast cancer."

About Regen BioPharma: Regen BioPharma, Inc., a  subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a  biotechnology company focused on identifying undervalued regenerative  medicine applications in the stem cell space and rapidly advancing these  technologies through pre-clinical and Phase I/II clinical trials. For  more information refer to the company's website  http://www.regenbiopharma.com/

About Benitec Biopharma Limited: Benitec Biopharma  Limited is an ASX-listed biotechnology company (ASX: BLT) based in  Sydney, Australia. The company has a pipeline of in-house and partnered  therapeutic programs based on its patented gene-silencing technology,  ddRNAi. Benitec is developing treatments for chronic and  life-threatening human conditions such as hepatitis C, hepatitis B, wet  age-related macular degeneration, cancer-associated pain, drug resistant  lung cancer and oculopharyngeal muscular dystrophy based on this  technology. In addition, Benitec has licensed ddRNAi technology to other  biopharmaceutical companies who are progressing their programs towards  the clinic for applications including HIV/AIDS, retinitis pigmentosa and  Huntington's disease. For more information on Benitec refer to the  Company's website at www.benitec.com.

Disclaimer: This news release may contain  forward-looking statements. Forward-looking statements are inherently  subject to risks and uncertainties, some of which cannot be predicted or  quantified. Future events and actual results could differ materially  from those set forth in, contemplated by, or underlying the  forward-looking statements. The risks and uncertainties to which forward  looking statements are subject include, but are not limited to, the  effect of government regulation, competition and other material risks.

de.advfn.com/p.php

 

 

null  

kurs wurde wieder unter die  0,0034 gedrückt, mit mini Umsatz, die 0,0034 ist die ema 100.

geht's darüber geht es auch über die ema 200 0,0037

die  ema 20 bei 0,0032 muss dann aber zur kaufmarke werden, spätestens die ema 50 bei 0,0031...

darunter ist es wieder bitter  

... ist schon 2 Tage alt... wurde vor 2 Tage bereits in Australien announced!  

 

3x wurde die 0,003 gekauft  

so ein Spielverderber ;)